中欣氟材(002915.SZ)半年度淨利潤預增103.65%-108.81%
格隆匯7月13日丨中欣氟材(002915.SZ)公佈,預計2021年半年度歸屬於上市公司股東的淨利潤7900萬元-8100萬元,同比增長103.65%-108.81%。業績變動原因如下:
1、報吿期內,隨着新冠疫情的有效控制,歸屬於上市公司股東的淨利潤較上年同期增長。報吿期內公司不斷提升經營管理能力,推行精細化管理,降本增效,業績保持穩健增長,盈利能力得以提升,銷售繼續穩定快速增長,渠道建設日趨完善。
2、報吿期內,子公司高寶科技的產品氫氟酸行業出現回暖,市場趨勢良好,同時2020年公司硫酸線的擴產建成,2021年外銷硫酸產量上升,使公司經營狀況逐步好轉。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.